The Immunoregulatory Roles of Antibody Glycosylation

Trends in Immunology

Volumn 38, Issue 5, 2017, Pages 358-372

  Jennewein, Madeleine F ^a   Alter, Galit ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VACCINE; POLYSACCHARIDE; PROTEIN BINDING;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; COMBINATORIAL CHEMISTRY; CYTOTOXICITY; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INFECTION; INFLAMMATION; MORPHOGENESIS; NONHUMAN; PHAGOCYTOSIS; PROTEIN GLYCOSYLATION; REVIEW; ANIMAL; BIOLOGICAL MODEL; CARBOHYDRATE ANALYSIS; CHEMISTRY; GLYCOSYLATION; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM;

ANIMALS; CARBOHYDRATE SEQUENCE; GLYCOSYLATION; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; MODELS, IMMUNOLOGICAL; POLYSACCHARIDES; PROTEIN BINDING; RECEPTORS, FC;

EID: 85016568747     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.02.004     Document Type: Review

References (98)

1. 1 Plotkin, S.A., Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17 (2010), 1055–1065.
2. 2 Excler, J.L., et al. Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines. Clin. Vaccine Immunol. 21 (2014), 1023–1036.
3. 3 Teo, A., et al. Functional antibodies and protection against blood-stage Malaria. Trends Parasitol. 32 (2016), 887–898.
4. 4 Ackerman, M.E., et al. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog., 12, 2016, e1005315.
5. 5 Kajihara, M., et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J. Virol. 86 (2012), 13467–13474.
6. 6 Goede, V., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370 (2014), 1101–1110.
7. 7 Junttila, T.T., et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 70 (2010), 4481–4489.
8. 8 Sondermann, P., Szymkowski, D.E., Harnessing Fc receptor biology in the design of therapeutic antibodies. Curr. Opin. Immunol. 40 (2016), 78–87.
9. 9 Scott, A.M., et al. Antibody therapy of cancer. Nat. Rev. Cancer 12 (2012), 278–287.
10. 10 Vidarsson, G., et al. IgG subclasses and allotypes: from structure to effector functions. Front Immunol., 5, 2014, 520.
11. 11 Pincetic, A., et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15 (2014), 707–716.
12. 12 Takai, T., Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2 (2002), 580–592.
13. 13 Hessell, A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007), 101–104.
14. 14 Ahmad, R., et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21 (2001), 227–233.
15. 15 Co, M.D., et al. Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 influenza in children. Viral Immunol. 27 (2014), 375–382.
16. 16 Schroeder, H.W. Jr., Cavacini, L., Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125 (2010), S41–S52.
17. 17 Pucic, M., et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol. Cell Proteomics, 10, 2011 M111.010090.
18. 18 Matthews, A.J., et al. Regulation of immunoglobulin class-switch recombination: choreography of noncoding transcription, targeted DNA deamination, and long-range DNA repair. Adv. Immunol. 122 (2014), 1–57.
19. 19 Jung, S., et al. Shutdown of class switch recombination by deletion of a switch region control element. Science 259 (1993), 984–987.
20. 20 Jung, D., et al. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu. Rev. Immunol. 24 (2006), 541–570.
21. 21 Bruhns, P., et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113 (2009), 3716–3725.
22. 22 Einarsdottir, H., et al. H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn. Transfusion 54 (2014), 665–671.
23. 23 Stapleton, N.M., et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun., 2, 2011, 599.
24. 24 Rosner, T., et al. An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. Br. J. Haematol. 161 (2013), 282–286.
25. 25 Krapp, S., et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325 (2003), 979–989.
26. 26 Ahmed, A.A., et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 426 (2014), 3166–3179.
27. 27 van de Bovenkamp, F.S., The emerging importance of IgG Fab glycosylation in immunity. J Immunol. 196 (2016), 1435–1441.
28. 28 Subedi, G.P., Barb, A.W., The structural role of antibody N-glycosylation in receptor interactions. Structure 23 (2015), 1573–1583.
29. 29 Lu, J., et al. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 833–838.
30. 30 Stanley, P., et al. N-glycans. Varki, A., (eds.) Essentials of Glycobiology, 2nd edn, 2009, Cold Spring Harbor Laboratory Press.
31. 31 Masuda, K., et al. Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Lett. 473 (2000), 349–357.
32. 32 Nishima, W., et al. Effect of bisecting GlcNAc and core fucosylation on conformational properties of biantennary complex-type N-glycans in solution. J. Phys. Chem. B 116 (2012), 8504–8512.
33. 33 Malhotra, R., et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1 (1995), 237–243.
34. 34 Thomann, M., et al. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol. Immunol. 73 (2016), 69–75.
35. 35 Anthony, R.M., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008), 373–376.
36. 36 Kaneko, Y., et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673.
37. 37 Washburn, N., et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E1297–E1306.
38. 38 Anthony, R.M., et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475 (2011), 110–113.
39. 39 Sondermann, P., et al. General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 9868–9872.
40. 40 Yu, X., et al. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J. Mol. Biol. 425 (2013), 1253–1258.
41. 41 Seite, J.F., et al. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116 (2010), 1698–1704.
42. 42 Massoud, A.H., et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J. Allergy Clin. Immunol. 133 (2014), 853–863 e5.
43. 43 Haga, C.L., et al. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 9770–9775.
44. 44 Shields, R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002), 26733–26740.
45. 45 Shinkawa, T., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003), 3466–3473.
46. 46 Sondermann, P., et al. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406 (2000), 267–273.
47. 47 Ferrara, C., et al. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281 (2006), 5032–5036.
48. 48 Ferrara, C., et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 12669–12674.
49. 49 Davies, J., et al. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74 (2001), 288–294.
50. 50 Kurimoto, A., et al. The absence of core fucose up-regulates GnT-III and Wnt target genes: a possible mechanism for an adaptive response in terms of glycan function. J. Biol. Chem. 289 (2014), 11704–11714.
51. 51 Goodridge, H.S., et al. Mechanisms of Fc receptor and dectin-1 activation for phagocytosis. Traffic 13 (2012), 1062–1071.
52. 52 Getahun, A., Cambier, J.C., Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. Immunol. Rev. 268 (2015), 66–73.
53. 53 van Egmond, M., et al. Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity. Immunol. Rev. 268 (2015), 311–327.
54. 54 Boruchov, A.M., et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115 (2005), 2914–2923.
55. 55 Billadeau, D.D., Leibson, P.J., ITAMs versus ITIMs: striking a balance during cell regulation. J. Clin. Invest. 109 (2002), 161–168.
56. 56 Karsten, C.M., Kohl, J., The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217 (2012), 1067–1079.
57. 57 Noris, M., Remuzzi, G., Overview of complement activation and regulation. Semin. Nephrol. 33 (2013), 479–492.
58. 58 Diebolder, C.A., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343 (2014), 1260–1263.
59. 59 Zipfel, P.F., Skerka, C., Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9 (2009), 729–740.
60. 60 Ackerman, M.E., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest 123 (2013), 2183–2192.
61. 61 Pasek, M., et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients – changes during therapy. Glycoconj. J. 23 (2006), 463–471.
62. 62 Kapur, R., et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 123 (2014), 471–480.
63. 63 Menni, C., et al. Glycosylation of immunoglobulin G: role of genetic and epigenetic influences. PLoS One, 8, 2013, e82558.
64. 64 Parekh, R.B., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316 (1985), 452–457.
65. 65 Vuckovic, F., et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 67 (2015), 2978–2989.
66. 66 Clavel, C., et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 58 (2008), 678–688.
67. 67 Ben Mkaddem, S., et al. Shifting FcgammaRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J. Clin. Invest. 124 (2014), 3945–3959.
68. 68 Lood, C., et al. IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment?. Arthritis Rheum. 64 (2012), 2698–2706.
69. 69 Mahan, A.E., et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog., 12, 2016, e1005456.
70. 70 De Milito, A., et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103 (2004), 2180–2186.
71. 71 de Jong, S.E., et al. IgG1 Fc N-glycan galactosylation as a biomarker for immune activation. Sci. Rep., 6, 2016, 28207.
72. 72 Selman, M.H., et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol. Cell. Proteomics, 11, 2012 M111.014563.
73. 73 Knezevic, A., et al. Variability, heritability and environmental determinants of human plasma N-glycome. J. Proteome Res. 8 (2009), 694–701.
74. 74 Zoldos, V., et al. Genomics and epigenomics of the human glycome. Glycoconj. J. 30 (2013), 41–50.
75. 75 Huffman, J.E., et al. Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are associated with variation within the human plasma N-glycome of 3533 European adults. Hum. Mol. Genet. 20 (2011), 5000–5011.
76. 76 Rivinoja, A., et al. Elevated Golgi pH impairs terminal N-glycosylation by inducing mislocalization of Golgi glycosyltransferases. J. Cell. Physiol. 220 (2009), 144–154.
77. 77 Lauc, G., et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet., 9, 2013, e1003225.
78. 78 Kristic, J., et al. Glycans are a novel biomarker of chronological and biological ages. J. Gerontol. A Biol. Sci. Med. Sci. 69 (2014), 779–789.
79. 79 Chen, G., et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J. Proteomics 75 (2012), 2824–2834.
80. 80 Knezevic, A., et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology 20 (2010), 959–969.
81. 81 Chung, A.W., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med., 6, 2014, 228ra38.
82. 82 Yates, N.L., et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med., 6, 2014, 228ra39.
83. 83 Carragher, D.M., et al. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181 (2008), 4168–4176.
84. 84 Abboud, N., et al. A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 207 (2010), 2395–2405.
85. 85 Lu, L.L., et al. A functional role for antibodies in tuberculosis. Cell 167 (2016), 433–443 e14.
86. 86 Moore, J.S., et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 19 (2005), 381–389.
87. 87 Wren, L.H., et al. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138 (2013), 116–123.
88. 88 Wang, T.T., et al. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162 (2015), 160–169.
89. 89 Wang, J., et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol. Cell. Proteomics, 10, 2011 M110.004655.
90. 90 Omtvedt, L.A., et al. Glycan analysis of monoclonal antibodies secreted in deposition disorders indicates that subsets of plasma cells differentially process IgG glycans. Arthritis Rheum. 54 (2006), 3433–3440.
91. 91 Moremen, K.W., et al. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13 (2012), 448–462.
92. 92 Voss, M., et al. Shedding of glycan-modifying enzymes by signal peptide peptidase-like 3 (SPPL3) regulates cellular N-glycosylation. EMBO J. 33 (2014), 2890–2905.
93. 93 Bernardi, C., et al. Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS One, 8, 2013, e76540.
94. 94 Novokmet, M., et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci. Rep., 4, 2014, 4347.
95. 95 Jones, M.B., et al. Anti-inflammatory IgG production requires functional P1 promoter in beta-galactoside alpha2,6-sialyltransferase 1 (ST6Gal-1) gene. J. Biol. Chem. 287 (2012), 15365–15370.
96. 96 Roopenian, D.C., Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (2007), 715–725.
97. 97 Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119 (2012), 5640–5649.
98. 98 Arnold, J.N., et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25 (2007), 21–50.